Explore the words cloud of the VALUE-Dx project. It provides you a very rough idea of what is the project "VALUE-Dx" about.
The following table provides information about the project.
|Coordinator Country||Belgium [BE]|
|Total cost||13˙739˙927 €|
|EC max contribution||6˙799˙100 € (49%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-04-01 to 2023-03-31|
Take a look of project's partnership.
|1||UNIVERSITEIT ANTWERPEN||BE (ANTWERPEN)||coordinator||2˙282˙957.00|
|2||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||1˙716˙160.00|
|3||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||participant||730˙458.00|
|4||ACADEMISCH ZIEKENHUIS GRONINGEN||NL (GRONINGEN)||participant||305˙596.00|
|5||UNIVERSITA DEGLI STUDI DI VERONA||IT (VERONA)||participant||275˙409.00|
|6||THE HEALTH CORPORATION - RAMBAM||IL (HAIFA)||participant||226˙444.00|
|7||FONDAZIONE PENTA - FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES - ONLUS||IT (PADOVA)||participant||189˙444.00|
|8||EUROPEAN SOCIETY CLINICAL MICROBIOLOGY INFECTIOUS DISEASES (EUROPAISCHE GESELLSCHAFT FUR KLINISCHE MIKROBIOLOGIE INFEKTIONSKRANKHEITEN)||CH (BASEL)||participant||184˙649.00|
|9||EUROPEAN RESPIRATORY SOCIETY||CH (LAUSANNE)||participant||144˙902.00|
|10||NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE||UK (MANCHESTER)||participant||137˙793.00|
|11||UNIVERSIDAD DE LA RIOJA||ES (LA RIOJA)||participant||136˙693.00|
|12||GESUNDHEIT OSTERREICH GMBH||AT (WIEN)||participant||88˙520.00|
|13||FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS||CH (GENEVE)||participant||77˙858.00|
|14||THE UNIVERSITY OF EDINBURGH||UK (EDINBURGH)||participant||75˙765.00|
|15||BERRY CONSULTANTS LLP||UK (ABINGDON)||participant||72˙411.00|
|16||BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE||FR (LYON)||participant||66˙337.00|
|17||LUXEMBOURG INSTITUTE OF HEALTH||LU (LUXEMBOURG)||participant||37˙365.00|
|18||ZORGONDERZOEK NEDERLAND ZON||NL (DEN HAAG)||participant||34˙698.00|
|19||THE TRUSTEES OF BOSTON UNIVERSITY||US (BOSTON MA)||participant||15˙641.00|
|20||ACCELERATE DIAGNOSTICS SL||ES (CASTELLDEFELS)||participant||0.00|
|21||ALERE INTERNATIONAL LIMITED||IE (GALWAY)||participant||0.00|
|22||BD SWITZERLAND SARL||CH (EYSINS)||participant||0.00|
|24||BIOMERIEUX SA||FR (Marcy l'Etoile)||participant||0.00|
|25||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|26||THE WELLCOME TRUST LIMITED||UK (LONDON)||participant||0.00|
Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice.
VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests.
A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VALUE-DX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VALUE-DX" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More